– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial…
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase…
Plus now has $23 million in active awards support for the Company’s targeted radiotherapeutic pipeline Funding for pediatric brain cancer…
• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech,…
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for…
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as…
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer Feedback from FDA following Type B meeting…
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation…
ORION CORPORATION MANAGERS’ TRANSACTIONS 22 APRIL 2024 at 9.45 EEST Orion Corporation: Managers’ transactions – Veli-Matti Mattila Orion Corporation has…
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase…